Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir

Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir

Abstract Background HIV infection and antiretroviral treatment are associated with changes in lipid levels, insulin resistance and risk of cardiovascular disease (CVD). We investigated these changes in the first 96 weeks of treatment with low-dose stavudine or tenofovir regimens. Methods This is a s...

Full description

Bibliographic Details
Main Authors: Alinda G. Vos, Matthew F. Chersich, Kerstin Klipstein-Grobusch, Peter Zuithoff, Michelle A. Moorhouse, Samanta T. Lalla-Edward, Andrew Kambugu, N. Kumarasamy, Diederick E. Grobbee, Roos E. Barth, Willem D. Venter
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Retrovirology
Subjects:
HIV
South Africa
Uganda
India
Stavudine
Tenofovir
Online Access:http://link.springer.com/article/10.1186/s12977-018-0460-z

Internet

http://link.springer.com/article/10.1186/s12977-018-0460-z

Similar Items